Mutagenic Tests Confirm That New Acetylacetonate Pt(II) Complexes Induce Apoptosis in Cancer Cells Interacting with Nongenomic Biological Targets
Author(s) -
Sandra Angelica De Pascali,
F. Lugoli,
Antonella De Donno,
Francesco Paolo Fanizzi
Publication year - 2011
Publication title -
metal-based drugs
Language(s) - English
Resource type - Journals
ISSN - 0793-0291
DOI - 10.1155/2011/763436
Subject(s) - cisplatin , apoptosis , chemistry , in vitro , reactivity (psychology) , nucleobase , chelation , cytotoxicity , nucleophile , stereochemistry , cancer cell , dna , ames test , platinum , methionine , medicinal chemistry , biochemistry , salmonella , cancer , biology , organic chemistry , genetics , bacteria , medicine , alternative medicine , amino acid , chemotherapy , pathology , catalysis
New platinum(II) complexes [PtCl( O,O′ -acac)(L)] ( 1 ) and [Pt( O,O′ -acac)( γ -acac)(L)] ( 2 ) (L = DMSO, a ; DMS, b ) containing a single chelated ( O,O′ -acac) ( 1 ), or one chelated and one σ -bonded ( γ -acac) acetylacetonate ( 2 ) have been synthesized. The new Pt(II) complexes exhibited high in vitro cytotoxicity on cisplatin sensitive and resistant cell lines and showed negligible reactivity with nucleobases (Guo and 5′-GMP) but selective substitution of DMSO/DMS with soft biological nucleophiles, such as L-methionine. In order to assess the ability of the new complexes with respect to cisplatin to induce apoptosis by interaction with nongenomic targets, the Ames' test, a standard reverse mutation assay, was carried out on two Salmonella typhimurium strains (TA98 and TA100). Interestingly, the new complexes did not show the well-known mutagenic activity exhibited by cisplatin and are, therefore, able to activate apoptotic pathways without interacting with DNA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom